Lenvatinib and Pembrolizumab (Lenvima and Keytruda)

Abstract


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses Lenvima (lenvatinib) 20 mg (two 10 mg capsules) orally once daily in combination with Keytruda (pembrolizumab) administered as an IV infusion over 30 minutes every 3 weeks.
 Indication: In combination with pembrolizumab, for the treatment of adult patients with advanced (not amenable to curative surgery or radiation) or metastatic RCC with no prior systemic therapy for metastatic RCC.